There is good news for people living with MS.
Effective May 1, Saskatchewan residents now have access to yet another treatment for multiple sclerosis.
Ocrevus is the first MS medication approved to treat early primary progressive MS. It is also the 13th option for treating relapsing remitting MS, which is the most common form of the condition.
“Our government is committed to providing Saskatchewan residents with better access to innovative new treatment options,” Health Minister Jim Reiter said in a press release. “Ocrevus will be the first drug treatment option approved for the primary progressive form of multiple sclerosis. It offers a treatment option that may slow the progression of multiple sclerosis and improve patients’ quality of life.”
Last year, the provincial government spent an estimated $17 million on MS medications for eligible patients.
Approximately 3,700 people in Saskatchewan live with MS.
For more information on the approval process and income-assisted programs, contact the Drug Plan and Extended Benefits Branch at 1-800-667-7581.
Meanwhile, don't forget that the annual MS Walk will be held at Sunningdale School on Sunday, May 26. Check-in time is at 9 a.m., with the walk starting at 10. For more information on how to donate or register, visit the MS Society of Canada’s webpage.
